Japan Antiemetic Drugs Market Insight
Published: 28 May 2026 | Report Format: Electronic (PDF)
Japan’s antiemetics drugs market is seeing constant growth at a rate of 5.74% CAGR due to an increase in cancer cases, chemotherapy procedures, and demand for better treatments of nausea and vomiting
Japan Antiemetic Drugs Market Insights Forecasts to 2035
- The Japan Antiemetic Drugs Market Size Was Estimated at USD 293.7 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.74 % from 2025 to 2035
- The Japan Antiemetic Drugs Market Size is Expected to Reach USD 513.3 Million by 2035
Notable Insights for Japan Antiemetic Drugs Market
- In terms of drug type, the Japan antiemetic drugs market was valued at about 38-40% in 2025 due to high utilization in CINV treatment and post-operative nausea due to increasing consumption in CINV therapy.
- In terms of application, chemotherapy-induced nausea and vomiting applications were responsible for about 44-46% of the Japan antiemetic drugs market value in 2025, driven by an increase in cancer treatments and high adoption of oncology supportive therapy options.
- Advanced oncology treatment infrastructure along with increased emphasis on supportive cancer care treatment options in Japan is expected to result in growing adoption of next-generation antiemetic drugs and therapies.
- Growing adoption of long-acting injectable antiemetics, AI-driven monitoring and precision oncology supportive therapies, as well as combination therapy approaches are anticipated to present promising growth opportunities for companies in the Japanese market.
Download the eBook (ToC)
Why Buy This Report
- Gain comprehensive insights into the Japan antiemetic drugs market, including market size, growth trends, competitive landscape, and future forecast analysis driving the supportive oncology therapeutics industry.
- Analyze increasing demand for serotonin receptor antagonists, neurokinin receptor antagonists, chemotherapy supportive care therapies, and advanced nausea management solutions across Japan.
- Identify high-growth investment opportunities through detailed evaluation of oncology treatment trends, antiemetic drug developments, injectable therapy innovations, and strategic healthcare infrastructure advancements shaping the Japan antiemetic drugs market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Antiemetic Drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment Market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the Market.
Top Companies in Japan Antiemetic Drugs Market
- Pfizer Inc.
- Merck & Co., Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- GSK plc
- Johnson & Johnson Services, Inc.
- Baxter International Inc.
- Eagle Pharmaceuticals, Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Other
Recent Developments:
- In February 2026, pharmaceutical companies accelerated investments in long-acting antiemetic formulations and combination nausea management therapies to improve chemotherapy supportive care outcomes.
Market Segmentation:
Japan Antiemetic Drugs Market, By Drug Class
- Serotonin Receptor Antagonists
- Neurokinin Receptor Antagonists
- Dopamine Receptor Antagonists
- Anticholinergics
- Antihistamines
- Others
Japan Antiemetic Drugs Market, By Application
- Chemotherapy-Induced Nausea & Vomiting
- Post-Operative Nausea & Vomiting
- Gastroenteritis
- Motion Sickness
- Pregnancy-Induced Nausea
- Others
Japan Antiemetic Drugs Market, By End User
- Hospitals
- Oncology Centers
- Ambulatory Surgical Centers
- Home Care Settings
- Others
Expert Views:
Japan antiemetic drug market is expected to see substantial growth in the coming years, mainly because cancer prevalence keeps climbing, chemotherapy procedures are rising too, and people are investing more into supportive oncology care technologies. At the same time, progress in long-acting antiemetic formulations, AI enabled healthcare monitoring systems, precision supportive care platforms, and next generation nausea management therapies is likely to push the market forward across Japan. Also, more funding into oncology treatment ecosystems, pharmaceutical innovation, and smart patient care technologies should open up solid growth chances for players working in the Japan antiemetic drugs industry.
Author: Komal and Radhika By Spherical Insights and Consulting